Longer intervals between SARS-CoV-2 infection and mRNA-1273 doses improve the neutralization of different variants of concern
- PMID: 36929737
- DOI: 10.1002/jmv.28679
Longer intervals between SARS-CoV-2 infection and mRNA-1273 doses improve the neutralization of different variants of concern
Abstract
The humoral immune response against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern elicited by vaccination was evaluated in COVID-19 recovered individuals (Rec) separated 1-3 months (Rec2m) or 4-12 months (Rec9m) postinfection and compared to the response in naïve participants. Antibody-mediated immune responses were assessed in 66 participants by three commercial immunoassays and a SARS-CoV-2 lentiviral-based pseudovirus neutralization assay. Immunoglobulin (Ig) levels against SARS-CoV-2 spike were lower in naïve participants after two doses than in Rec after a single dose (p < 0.05). After two doses in Rec, levels of total Ig to receptor-binding domain were significantly increased in Rec9m compared to Rec2m (p < 0.001). The neutralizing potency observed in Rec9m was consistently higher than in Rec2m against variants of concern (VOCs) Alpha, Beta, Delta, and BA.1 sublineage of Omicron with 2.2-2.8-fold increases. Increasing the interval between SARS-CoV-2 infection and the vaccination with messenger RNA-based vaccines to more than 3 months generates a more efficient heterologous humoral immune response against VOCs by allowing enough time to mount a strong recall memory B cell response.
Keywords: Omicron; hybrid immunity; mRNA-1273; neutralizing antibodies; timing of vaccination.
© 2023 The Authors. Journal of Medical Virology published by Wiley Periodicals LLC.
References
REFERENCES
-
- Dan JM, Mateus J, Kato Y, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science. 2021;371(6529):eabf4063. doi:10.1126/science.abf4063
-
- Sahin U, Muik A, Derhovanessian E, et al. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature. 2020;586(7830):594-599. doi:10.1038/s41586-020-2814-7
-
- Chandrashekar A, Liu J, Martinot AJ, et al. SARS-CoV-2 infection protects against rechallenge in Rhesus macaques. Science. 2020;369(6505):812-817. doi:10.1126/science.abc4776
-
- Deng W, Bao L, Liu J, et al. Primary exposure to SARS-CoV-2 protects against reinfection in Rhesus macaques. Science. 2020;369(6505):818-823. doi:10.1126/science.abc5343
-
- Krammer F, Srivastava K, Alshammary H, et al. Antibody responses in seropositive persons after a single dose of SARS-CoV-2 mRNA vaccine. N Engl J Med. 2021;384(14):1372-1374. doi:10.1056/NEJMc2101667
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources